Search Results - Cebotarescu, V.

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection

    One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection by Bazinet, M, Pantea, V, Cebotarescu, V, Cojuhari, L, Jimbei, P, Krawczyk, A, Vaillant, A

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    LO2 : Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in caucasian patients with chronic HBV/HDV co-infection

    LO2 : Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in caucasian patients with chronic HBV/HDV co-infection by Bazinet, M, Pantea, V, Cebotarescu, V, Cojuhari, L, Jimbei, P, Vaillant, A

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection

    Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatm... by Bazinet, M, Pantea, V, Placinta, G, Moscalu, I, Cebotarescu, V, Cojuhari, L, Jimbei, P, Iarovoi, L, Smesnoi, V, Musteata, T, Jucov, A, Krawczyk, A, Vaillant, A

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection

    Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infect... by Bazinet, M, Pantea, V, Cebotarescu, V, Cojuhari, L, Jimbei, P, Albrecht, J, Schmid, P, Krawczyk, A, Karimzadeh, H, Roggendorf, M, Vaillant, A

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    FRI-326 - Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study

    FRI-326 - Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co... by Bazinet, M., Pantea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Vaillant, A.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study

    Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection... by Bazinet, M., Pantea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Vaillant, A.

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    LBP-507 - One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection

    LBP-507 - One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infectio... by Bazinet, M., Pantea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Krawczyk, A., Vaillant, A.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    FRI-343 - Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a

    FRI-343 - Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pe... by Vaillant, A., Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., Jimbei, P., Iarovoi, L., Smesnoi, V., Musteata, T., Jucov, A., Krawczyk, A.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a

    Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated in... by Vaillant, A., Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., Jimbei, P., Iarovoi, L., Smesnoi, V., Musteata, T., Jucov, A., Krawczyk, A.

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  10. 10
    THU-154 - Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection

    THU-154 - Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a... by Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., Jimbei, P., Iarovoi, L., Smesnoi, V., Musteata, T., Jucov, A., Krawczyk, A., Vaillant, A.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    FRI-105 - Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection

    FRI-105 - Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV... by Bazinet, M., Pantea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Albrecht, J., Schmid, P., Krawczyk, A., Karimzadeh, H., Roggendorf, M., Vaillant, A.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: